Paul Chaplin, Bavarian Nordic CEO

J&J ends he­pati­tis B and HPV por­tions of Bavar­i­an Nordic col­lab

John­son & John­son’s Janssen end­ed its col­lab­o­ra­tion and li­cens­ing agree­ments with Bavar­i­an Nordic con­cern­ing vac­cines for he­pati­tis B virus and hu­man pa­pil­lo­mavirus­es.

J&J and the Dan­ish vac­cines biotech will con­tin­ue their tie-up as it re­lates to HIV and Ebo­la, Janssen said Mon­day. The duo an­nounced the HPV pact in De­cem­ber 2015 at a to­tal po­ten­tial val­ue of $171 mil­lion, and the he­pati­tis B and HIV work came via a Ju­ly 2017 agree­ment worth up to $879 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.